ARTICLE SUMMARY:
Six-year-old Exosome Diagnostics is building a portfolio of exosomal RNA-based tests that utilize biofluid samples, joining a slew of other young companies in the high-profile liquid biopsy space. The first applications are in cancer, the treatment of which is shifting from location-based strategies to strategies driven by genomic alterations, making accurate and sensitive molecular tests more vital than ever.
In 2007, Johan Skog, PhD, an expert in virology, was on the junior faculty at Harvard Medical School’s Massachusetts General Hospital (MGH). He was studying glioblastoma stem cells when he noticed microvesicles clustered around the tumor cells.
